CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma and Access in Turkey

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Sep 13

PMID 39267974

Authors

Goker Hakan

Kelkitli Engin

Karakulak Aladag Elifcan

Demiroglu Haluk

Turgut Mehmet

Kambhampati Suman

Krem Maxwell

Affiliations

Soon will be listed here.

Abstract

The past decade has seen the development of immunotherapy for the treatment of multiple myeloma (MM), beginning with monoclonal antibodies (mAbs) in the relapsed and refractory setting and culminating in the market approval of chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs). The medical community is evaluating the efficacy and safety of these targeted immunotherapies, most of which currently target B-cell maturation antigen (BCMA) on the surface of plasma cells. Two anti-BCMA CAR-T products are available for treating relapsed or refractory MM: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). Ide-cel and cilta-cel demonstrate the ability to induce deep responses in heavily pretreated diseases, including patients with triple-class-refractory and penta-refractory diseases. However, there are key similarities and differences regarding these agents, unknowns regarding their comparative efficacy and toxicity, and mechanisms underlying resistance to these new immunotherapies. This review discusses CAR-T cell therapy in relapsed refractory MM, with a focus on efficacy, toxicities, and the evolving trajectories of these therapies in the USA, as well as access in Turkey.

References

Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan W . FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022; 28(9):1759-1764. PMC: 9064878. DOI: 10.1158/1078-0432.CCR-21-3803. View

Jain M, Smith M, Shah N . How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023; 141(20):2430-2442. PMC: 10329191. DOI: 10.1182/blood.2022017414. View

Hashmi H, Hansen D, Peres L, Castaneda Puglianini O, Freeman C, De Avila G . Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2023; 109(5):1514-1524. PMC: 11063864. DOI: 10.3324/haematol.2023.283888. View

Hansen D, Sidana S, Peres L, Colin Leitzinger C, Shune L, Shrewsbury A . Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023; 41(11):2087-2097. PMC: 10082273. DOI: 10.1200/JCO.22.01365. View

Dingli D, Ailawadhi S, Bergsagel P, Buadi F, Dispenzieri A, Fonseca R . Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017; 92(4):578-598. PMC: 5554888. DOI: 10.1016/j.mayocp.2017.01.003. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Heslop H . Data mining for second malignancies after CAR-T. Blood. 2024; 143(20):2023-2024. DOI: 10.1182/blood.2024024446. View

Oluwole O, Bouabdallah K, Munoz J, de Guibert S, Vose J, Bartlett N . Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021; 194(4):690-700. PMC: 8457222. DOI: 10.1111/bjh.17527. View

Rejeski K, Jain M, Smith E . Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma. Transplant Cell Ther. 2023; 29(7):418-428. PMC: 10330792. DOI: 10.1016/j.jtct.2023.04.007. View

10.

San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M . Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023; 389(4):335-347. DOI: 10.1056/NEJMoa2303379. View

11.

Dima D, Rashid A, Davis J, Shune L, Abdallah A, Li H . Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. Br J Haematol. 2024; 204(4):1293-1299. DOI: 10.1111/bjh.19302. View

12.

Martin T, Usmani S, Schecter J, Vogel M, Jackson C, Deraedt W . Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021; 37(10):1779-1788. DOI: 10.1080/03007995.2021.1953456. View

13.

Zhang X, Zhang H, Lan H, Wu J, Xiao Y . CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol. 2023; 14:1101495. PMC: 9986336. DOI: 10.3389/fimmu.2023.1101495. View

14.

Atallah R, Ahmed N, Ayoobkhan F, Saif M, Logan E, Shrestha A . TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians. Transplant Cell Ther. 2024; 30(9):925.e1-925.e6. DOI: 10.1016/j.jtct.2024.05.011. View

15.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

16.

Martin T, Usmani S, Berdeja J, Agha M, Cohen A, Hari P . Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2022; 41(6):1265-1274. PMC: 9937098. DOI: 10.1200/JCO.22.00842. View

17.

Hines M, Knight T, McNerney K, Leick M, Jain T, Ahmed S . Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023; 29(7):438.e1-438.e16. PMC: 10330221. DOI: 10.1016/j.jtct.2023.03.006. View

18.

Anderson Jr L, Dhakal B, Jain T, Oluwole O, Shah G, Sidana S . Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular.... Transplant Cell Ther. 2023; 30(1):17-37. PMC: 10873054. DOI: 10.1016/j.jtct.2023.10.022. View

19.

Kumar S, Rajkumar V, Kyle R, van Duin M, Sonneveld P, Mateos M . Multiple myeloma. Nat Rev Dis Primers. 2017; 3:17046. DOI: 10.1038/nrdp.2017.46. View

20.

Hines M, Keenan C, Alfaro G, Cheng C, Zhou Y, Sharma A . Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021; 194(4):701-707. PMC: 8756350. DOI: 10.1111/bjh.17662. View